Laddar...
BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models
Drug-tolerant “persister” tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones...
Sparad:
| I publikationen: | Cancer Cell |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6945775/ https://ncbi.nlm.nih.gov/pubmed/31085176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.04.005 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|